The Diabetic Heart Failure with Preserved Ejection Fraction Phenotype: Is it Real and Is It Worth Targeting Therapeutically?

Circulation

Volumn 135, Issue 8, 2017, Pages 736-740

  Lindman, Brian R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes mellitus; Editorials; ejection fraction; heart failure; therapy

Indexed keywords

INSULIN; IRBESARTAN;

CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG TARGETING; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; HEART FAILURE; HEART STROKE VOLUME;

DIABETES MELLITUS; HEART FAILURE; HUMANS; PHENOTYPE; STROKE VOLUME;

EID: 85009343009     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.025957     Document Type: Review

References (16)

1. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ, Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 2016 134 73 90. doi: 10.1161/CIRCULATIONAHA.116.021884.
2. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP, Tschöpe C, Metra M, Hummel SL, Edelmann F, Ambrosio G, Stewart Coats AJ, Filippatos GS, Gheorghiade M, Anker SD, Levy D, Pfeffer MA, Stough WG, Pieske BM, New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014 35 2797 2815. doi: 10.1093/eurheartj/ehu204.
3. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC, Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015 131 269 279. doi: 10.1161/CIRCULATIONAHA.114.010637.
4. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J, Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail 2015 17 925 935. doi: 10.1002/ejhf.327.
5. Paulus WJ, Tschöpe C, A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013 62 263 271. doi: 10.1016/j.jacc.2013.02.092.
6. Lam CS, Brutsaert DL, Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction. J Am Coll Cardiol 2012 60 1787 1789. doi: 10.1016/j.jacc.2012.08.004.
7. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ, CHARM investigators Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008 29 1377 1385. doi: 10.1093/eurheartj/ehn153.
8. Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B, Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 2010 105 373 377. doi: 10.1016/j.amjcard.2009.09.041.
9. Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, Redfield MM, Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol 2014 64 541 549. doi: 10.1016/j.jacc.2014.05.030.
10. Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Køber L, McKelvie RS, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray JJV, Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation 2017 135 724 735. doi: 10.1161/CIRCULATIONAHA.116.024593.
11. From AM, Scott CG, Chen HH, The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010 55 300 305. doi: 10.1016/j.jacc.2009.12.003.
12. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE investigators Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 359 2456 2467. doi: 10.1056/NEJMoa0805450.
13. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbély A, van der Velden J, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ, Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008 117 43 51. doi: 10.1161/CIRCULATIONAHA.107.728550.
14. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720.
15. Sharma K, Kass DA, Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 2014 115 79 96. doi: 10.1161/CIRCRESAHA.115.302922.
16. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O'Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M, Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail 2014 2 97 112. doi: 10.1016/j.jchf.2013.10.006.